Topical corticosteroids remain a cornerstone of atopic dermatitis care, but steroid phobia and a growing roster of nonsteroidal agents are reshaping how clinicians use them. On this episode…
Exosomes in dermatology are moving closer to a regulatory pathway, and a new remibrutinib label update is changing how clinicians approach symptomatic dermographism. Todd Schlesinger, MD, shares the…
Douglas DiRuggiero, DMSc, MHS, PA-C, shares how oral and targeted therapies in psoriasis are discussed at Horizons in Advanced Practice and what he expects across inflammatory skin disease…
Why can’t some Medicare patients get advanced therapy for skin disease, even after they’ve failed standard topicals? In this interview from the 2026 Horizons in Advanced Practice meeting…
Patients with moderate-to-severe atopic dermatitis who respond early to nemolizumab (Nemluvio) tend to keep improving with continued treatment. That finding comes from a post hoc analysis of the…
Atopic dermatitis late-breakers from EADV 2026 in Vienna are the focus of this Dermatology Times interview with Christopher Bunick, MD, PhD, associate professor of dermatology at Yale School…
Atopic dermatitis (AD) affects more than 31 million people in the United States, about 1 in 10, and it remains underestimated and underappreciated for its impact. The State…
Cytokines and chemokines as a possible biomarker in atopic dermatitis Kenji Kabashima MD PhD | Kyoto, Japan Professor, Department of Dermatology Kyoto University Graduate School of Medicine
